152 related articles for article (PubMed ID: 25222595)
1. An insight into advances in the pathogenesis and therapeutic strategies of spinocerebellar ataxia type 3.
Wu Y; Peng Y; Wang Y
Rev Neurosci; 2015; 26(1):95-104. PubMed ID: 25222595
[TBL] [Abstract][Full Text] [Related]
2. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
3. From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation.
Da Silva JD; Teixeira-Castro A; Maciel P
Neurotherapeutics; 2019 Oct; 16(4):1009-1031. PubMed ID: 31691128
[TBL] [Abstract][Full Text] [Related]
4. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
[TBL] [Abstract][Full Text] [Related]
5. Autophagy Promoted the Degradation of Mutant ATXN3 in Neurally Differentiated Spinocerebellar Ataxia-3 Human Induced Pluripotent Stem Cells.
Ou Z; Luo M; Niu X; Chen Y; Xie Y; He W; Song B; Xian Y; Fan D; OuYang S; Sun X
Biomed Res Int; 2016; 2016():6701793. PubMed ID: 27847820
[TBL] [Abstract][Full Text] [Related]
6. Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.
Raj K; Akundi RS
Mol Neurobiol; 2021 Jul; 58(7):3095-3118. PubMed ID: 33629274
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells.
Ouyang S; Xie Y; Xiong Z; Yang Y; Xian Y; Ou Z; Song B; Chen Y; Xie Y; Li H; Sun X
Stem Cells Dev; 2018 Jun; 27(11):756-770. PubMed ID: 29661116
[TBL] [Abstract][Full Text] [Related]
8. ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice.
Schuster KH; Zalon AJ; DiFranco DM; Putka AF; Stec NR; Jarrah SI; Naeem A; Haque Z; Zhang H; Guan Y; McLoughlin HS
Mol Ther; 2024 May; 32(5):1359-1372. PubMed ID: 38429929
[TBL] [Abstract][Full Text] [Related]
9. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
Li X; Liu H; Fischhaber PL; Tang TS
Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
[TBL] [Abstract][Full Text] [Related]
10. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
[TBL] [Abstract][Full Text] [Related]
11. [Recent advances in molecular genetics of spinocerebellar ataxia type 3/Machado-Joseph disease].
Jia D; Jiang H; Tang B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):660-2. PubMed ID: 19065526
[TBL] [Abstract][Full Text] [Related]
12. RAN Translation of the Expanded CAG Repeats in the SCA3 Disease Context.
Jazurek-Ciesiolka M; Ciesiolka A; Komur AA; Urbanek-Trzeciak MO; Krzyzosiak WJ; Fiszer A
J Mol Biol; 2020 Dec; 432(24):166699. PubMed ID: 33157084
[TBL] [Abstract][Full Text] [Related]
13. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
[TBL] [Abstract][Full Text] [Related]
14. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP
Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324
[TBL] [Abstract][Full Text] [Related]
15. Induced pluripotent stem cell - derived neurons for the study of spinocerebellar ataxia type 3.
Hansen SK; Stummann TC; Borland H; Hasholt LF; Tümer Z; Nielsen JE; Rasmussen MA; Nielsen TT; Daechsel JC; Fog K; Hyttel P
Stem Cell Res; 2016 Sep; 17(2):306-317. PubMed ID: 27596958
[TBL] [Abstract][Full Text] [Related]
16. Deficiency in classical nonhomologous end-joining-mediated repair of transcribed genes is linked to SCA3 pathogenesis.
Chakraborty A; Tapryal N; Venkova T; Mitra J; Vasquez V; Sarker AH; Duarte-Silva S; Huai W; Ashizawa T; Ghosh G; Maciel P; Sarkar PS; Hegde ML; Chen X; Hazra TK
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8154-8165. PubMed ID: 32205441
[TBL] [Abstract][Full Text] [Related]
17. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3.
Boy J; Schmidt T; Wolburg H; Mack A; Nuber S; Böttcher M; Schmitt I; Holzmann C; Zimmermann F; Servadio A; Riess O
Hum Mol Genet; 2009 Nov; 18(22):4282-95. PubMed ID: 19666958
[TBL] [Abstract][Full Text] [Related]
18. Caffeic acid and resveratrol ameliorate cellular damage in cell and Drosophila models of spinocerebellar ataxia type 3 through upregulation of Nrf2 pathway.
Wu YL; Chang JC; Lin WY; Li CC; Hsieh M; Chen HW; Wang TS; Wu WT; Liu CS; Liu KL
Free Radic Biol Med; 2018 Feb; 115():309-317. PubMed ID: 29247688
[TBL] [Abstract][Full Text] [Related]
19. Gene editing as a therapeutic strategy for spinocerebellar ataxia type-3.
Déglon N
Rev Neurol (Paris); 2024 May; 180(5):378-382. PubMed ID: 38580500
[TBL] [Abstract][Full Text] [Related]
20. RNA Interference Therapy for Machado-Joseph Disease: Long-Term Safety Profile of Lentiviral Vectors Encoding Short Hairpin RNAs Targeting Mutant Ataxin-3.
Nóbrega C; Codêsso JM; Mendonça L; Pereira de Almeida L
Hum Gene Ther; 2019 Jul; 30(7):841-854. PubMed ID: 30760052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
